Bevacizumab (Avastin, Genentech, Inc.)is the first approved monoclonal antibody directed against vascular endothelial growth factor (VEGF) that has been widely used in clinical practice to treat several malignancies such as non-small cell lung cancer (NSCLC) (Cohen et al., 2007; Zahn et al., 2019; Garcia et al., 2020). Here, VEGFA is linked to non-small cell lung carcinoma.